Nature Immunology's AI Policy: What Immunology Authors Need to Know About Disclosure
Nature Immunology follows Springer Nature's AI policy with LLM use to be documented in the Methods section, plus guidance on single-cell analysis pipelines, immune repertoire data, and clinical immunology considerations.
Readiness scan
AI policy covered? See what Nature Immunology reviewers are likely to push back on.
The AI policy governs disclosure, not how the science is judged. Run the Free Readiness Scan with Nature Immunology as your target to see desk-rejection risk, likely reviewer concerns, and journal fit.
Quick answer: Immunology papers are getting more computational every year.
Between single-cell transcriptomics, spatial proteomics, systems immunology modeling, and the growing role of AI in predicting immune responses, the average Nature Immunology manuscript now contains significantly more bioinformatics than it did a decade ago. The journal's AI policy covers AI use across the research and publishing lifecycle and sorts it by risk level; established analysis software such as Seurat or Scanpy is not an AI writing tool. But for immunology authors juggling both, knowing where to draw the line matters.
Nature Immunology AI Policy at a Glance
- AI authorship: Prohibited. AI tools cannot be listed as authors and cannot take accountability for the work.
- AI disclosure: Document LLM use in the Methods section, as the journal's guidelines say. Springer Nature's policy asks authors to disclose AI use for trust and transparency (e.g., ChatGPT, Claude, Gemini).
- AI-generated images: Restricted. The journal does not permit images created with generative AI for cover artwork, and Springer Nature's policy lists creating photorealistic images (deepfakes) as not permitted.
- Language editing: Using an LLM to polish language is a permitted, low-risk use (disclosure enhances trust and transparency); extensive copy editing or writing support is permitted with oversight, verification and disclosure.
The policy
Nature Immunology follows the Springer Nature AI policy published on the Nature Portfolio editorial-policies page. The policy sorts AI use into green (permitted), amber (exercise caution) and red (not permitted) levels:
- AI can't be an author. No listing LLMs or generative AI tools as co-authors.
- LLM use should be documented in Methods. The journal's guidelines say use of an LLM should be properly documented in the Methods section. Naming the tool, describing how it was used and specifying which sections is the practical way to do that.
- Generative-AI images are restricted. The journal does not permit images created with generative AI (such as DALL-E, Stable Diffusion and Midjourney) for cover artwork, and the policy lists creating photorealistic images (deepfakes) as not permitted. The published text sets no separate rule for figures or graphical abstracts, so ask the handling editor before using a generative-AI image.
- Language polishing is permitted. Using an LLM to polish or refine language is a green-level use, and disclosure enhances trust and transparency. Extensive copy editing or writing support is amber-level: permitted with human oversight, verification and disclosure.
- Authors are fully responsible for all content.
The journal's editorial-policies page carries the same Springer Nature policy text, and the journal's own guidelines add the Methods documentation and cover-artwork points above.
Publisher-wide vs. journal-level implementation
The Springer Nature AI policy is set centrally, but how it plays out varies by journal because of the research community's characteristics:
Aspect | Springer Nature (general) | Nature Immunology (in practice) |
|---|---|---|
Policy text | Standard | Identical |
Computational content in papers | Varies | High and increasing |
scRNA-seq/CyTOF analysis | Some journals | Very common |
Clinical immunology content | Some journals | Significant subset |
Reviewer computational literacy | Varies | Generally high |
Community size | N/A | Small, interconnected |
The community size point matters for enforcement. Nature Immunology's authorship network is relatively concentrated, the same researchers appear as authors and reviewers. If your paper has an AI disclosure issue and it becomes known, word travels fast.
Single-cell analysis pipelines
Single-cell immunology is where most AI-related questions arise. A typical Nature Immunology scRNA-seq paper involves:
- Quality control and filtering
- Normalization and batch correction
- Dimensionality reduction (PCA, UMAP)
- Clustering and cell type annotation
- Differential expression analysis
- Trajectory inference
- Gene regulatory network analysis
If you used Copilot or ChatGPT to help write code for any of these steps, that's AI-assisted manuscript preparation (specifically, code generation) requiring disclosure. The analysis tools themselves, Seurat, Scanpy, Harmony, scVI, aren't AI writing tools and don't need to be disclosed under the AI policy (they go in standard Methods as analysis software).
Disclosure example for an scRNA-seq paper:
"Single-cell RNA-seq analysis was performed using Seurat v5 (R) and Scanpy (Python) as described in Methods. GitHub Copilot (Microsoft) was used to assist with writing custom R scripts for the cell type annotation pipeline. All scripts were validated against manual annotation of a reference dataset. ChatGPT (GPT-4, OpenAI) was used to improve the language of the Discussion section. The authors take full responsibility for the published content."
Immune repertoire analysis
TCR and BCR repertoire sequencing generates massive datasets that require specialized computational tools. If AI helped with writing analysis code for clonotype identification, CDR3 analysis, or repertoire diversity calculations, disclose it.
But don't confuse the analysis tools with writing tools. immunarch, MiXCR, and TRUST4 are bioinformatics software described in Methods. ChatGPT helping you write a wrapper script around these tools is AI-assisted code generation requiring separate disclosure.
Clinical immunology and patient data
Nature Immunology publishes translational and clinical immunology research involving patient samples. The same data privacy concerns that apply at Nature Medicine apply here: don't input patient data, clinical records, or identifiable information into cloud-based AI tools.
For papers involving autoimmune disease cohorts, vaccine trial immunogenicity data, or transplant immunology with patient outcomes, keep AI tools away from clinical interpretation sections.
Writing the disclosure
For a systems immunology paper:
"During manuscript preparation, the authors used ChatGPT (GPT-4, OpenAI) to improve the clarity of the Results and Discussion sections. The computational modeling described in this study (immune response ODE model) was developed and parameterized by the authors without AI assistance. The authors take full responsibility for the published content."
For a paper with multi-omics integration:
"The authors used Claude (Claude 3.5, Anthropic) to edit the Introduction for language clarity. GitHub Copilot (Microsoft) assisted with writing Python scripts for integrating CyTOF and scRNA-seq datasets. All integration code was validated against published reference datasets (see Methods: Data Integration Validation). No patient-identifiable data was processed through any cloud-based AI tool."
For a basic immunology paper:
"During preparation of this manuscript, the authors used ChatGPT (GPT-4, OpenAI) to improve the readability of the Methods section. All content was reviewed by the senior author (K.Y.). The authors take full responsibility for the content of the published article."
What requires disclosure
Use case | Disclosure required? | Immunology notes |
|---|---|---|
Standard grammar tools | Not addressed | The journal's guidelines ask for LLM use to be documented in Methods; the policy treats language polishing as permitted, with disclosure encouraged |
ChatGPT for language editing | Yes | Methods section |
AI for scRNA-seq code | Yes | Specify which pipeline steps |
Seurat/Scanpy usage | No (research tool) | Standard Methods description |
AI for flow cytometry analysis code | Yes | Confirm gating strategy was human-defined |
AI-generated immune cell diagrams | Ask the editor first | Generative-AI images are barred for cover artwork and photorealistic images (deepfakes) are not permitted; BioRender or similar design tools are ordinary alternatives |
AI for TCR/BCR repertoire code | Yes | Confirm validation of repertoire calls |
AI for figure legends | Yes | Part of the manuscript |
AI for literature search on cytokines | Yes | Describe scope |
AI for grant-to-paper text adaptation | Yes | Generating new manuscript text |
The flow cytometry gating strategy point is important. Gating decisions in flow and CyTOF experiments are scientific judgments that should be made by trained immunologists. If AI influenced your gating strategy, this isn't just a disclosure issue, it's a scientific integrity question. The analysis code can be AI-assisted, but the gating logic should come from the investigators.
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Consequences of non-disclosure
Springer Nature's policy says existing research integrity, ethics and editorial governance processes apply to all AI-related concerns. Nature Immunology's editorial policies page adds that the journal reserves the right to decline publication of a paper even after acceptance if it becomes apparent that there are serious problems with the scientific content or violations of its publishing policies.
Immunology community dynamics: Nature Immunology published 137 research articles in 2025, according to the journal's own research-articles listing. The immunology community is small enough that most researchers in a given subfield know each other. A publication ethics issue at this journal has outsized reputational consequences compared to a megajournal.
If your paper involves collaboration between immunology labs and computational biology groups, which is increasingly common, make sure both sides contribute to the AI disclosure. The wet-lab PI may not know that the bioinformatics collaborator used Copilot for the analysis pipeline, and the bioinformatics lead may not know that the first author used ChatGPT to rewrite the Introduction.
Comparison with other immunology journals
Feature | Nature Immunology | Immunity | Journal of Experimental Medicine | Journal of Immunology | Frontiers in Immunology |
|---|---|---|---|---|---|
Publisher | Springer Nature | Cell Press (Elsevier) | Rockefeller UP | AAI (Oxford UP) | Frontiers |
AI authorship | Prohibited | Prohibited | Prohibited | Prohibited | Prohibited |
Disclosure location | Methods | STAR Methods | Methods | Methods | Methods |
AI image ban | Cover artwork (no general ban in the policy text) | Yes | Yes | Yes | Yes |
Copy editing exemption | Language polishing permitted; disclosure encouraged | Implicit | Yes | Yes | Yes |
Impact factor range | ~25-30 | ~25-30 | ~11.6 | ~4-5 | ~5-7 |
scRNA-seq papers | Very common | Very common | Common | Common | Common |
Immunity (Cell Press) uses STAR Methods format, so your AI disclosure goes in Method Details rather than a free-form Methods section. The Journal of Immunology (AAI) follows Oxford University Press guidelines. Frontiers in Immunology follows Frontiers' publisher-wide policy. Requirements differ in detail between these journals, so check each current policy page before submitting.
For authors choosing between Nature Immunology and Immunity: the disclosure format differs (Methods vs. STAR Methods), so read each journal's current policy before you submit.
Timeline and policy stability
Springer Nature now presents its AI policy as a risk-assessment framework with green (permitted), amber (exercise caution) and red (not permitted) levels, applied across authors, peer reviewers and editors. The policy page says these policies will be reviewed periodically to stay aligned with evolving technologies, regulations and community expectations, so older summaries built around a short list of rules may be out of date.
This matters for immunology researchers planning multi-year projects. If you're midway through a study that won't be submitted for another year, re-read the policy page and the journal's guidelines at submission time rather than relying on today's summary.
Practical advice for Nature Immunology submissions
For single-cell immunology papers:
- Keep a record of which analysis code was AI-assisted and which was written from scratch
- If your cell type annotations used any AI-based automatic annotation tools, describe these as analysis methods, not in the AI writing disclosure
- Validate all AI-generated code against published reference datasets before including in the paper
For vaccine and clinical immunology:
- Don't process participant immunological data through cloud AI tools
- Keep AI away from efficacy claims and clinical outcome descriptions
- If your paper includes immune correlates of protection, the interpretation should be entirely human-driven
For mechanistic immunology papers:
- AI can help with language, but descriptions of signaling pathways, knockout phenotypes, and molecular mechanisms should reflect what you observed, not what an LLM predicts based on training data
- Be careful with AI-edited Discussion sections, LLMs may insert claims about immune mechanisms that sound plausible but don't match your specific experimental system
Before submission checklist:
- [ ] AI disclosure in Methods with tool names, versions, use cases
- [ ] Research tools (Seurat, Scanpy, FlowJo) described in standard Methods
- [ ] Writing/code tools (ChatGPT, Copilot) in separate AI disclosure
- [ ] No patient/participant data processed through cloud AI
- [ ] No generative AI images or pathway diagrams
- [ ] All co-authors aware of AI disclosure
- [ ] AI-assisted code validated independently
A Nature Immunology submission readiness check can help verify your Nature Immunology submission meets editorial and disclosure standards.
What should you do about Nature Immunology's's AI policy?
Comply proactively if:
- You used any AI tool (ChatGPT, Grammarly, Copilot) during manuscript preparation
- The journal asks for LLM use to be documented in the Methods section
- Your institution has its own AI use policy that may be stricter
Less concerned if:
- You used AI only for grammar/spell checking (Springer Nature's policy treats language polishing as permitted, with disclosure encouraged)
- The journal does not have a formal AI policy yet
- Your use was limited to literature search or reference management
Frequently asked questions
Yes, under Springer Nature's AI policy, which sorts AI use by risk level: language polishing is permitted, extensive copy editing or writing support is permitted with oversight and disclosure, and AI use that replaces scholarly judgement or lacks transparency is not permitted. The journal's guidelines say use of an LLM should be documented in the Methods section. AI can't be listed as an author, and the journal does not permit generative-AI images for cover artwork.
Not in its core text. Nature Immunology's editorial-policies page carries the same Nature Portfolio AI policy text as the Nature Portfolio editorial-policies page, and the journal's own guidelines add that LLM use should be documented in the Methods section and that generative-AI images are not permitted for cover artwork.
If AI assisted with writing analysis code for scRNA-seq, CyTOF, or CITE-seq pipelines, disclose this in Methods and specify which analysis steps were AI-assisted. The bioinformatics tools themselves (Seurat, Scanpy, FlowJo) aren't covered by the AI disclosure policy. Keep research tools and writing tools clearly separated in your disclosure.
The journal's guidelines bar generative-AI images (such as from DALL-E, Stable Diffusion and Midjourney) from cover artwork, and Springer Nature's policy lists creating photorealistic images (deepfakes) as not permitted. The published text sets no separate rule for pathway diagrams in figures, so ask the handling editor before using a generative-AI image. Diagrams drawn in BioRender, Illustrator, or similar design tools are ordinary figure work.
Springer Nature's policy says existing research integrity, ethics and editorial governance processes apply to all AI-related concerns, and Nature Immunology's editorial policies page says the journal reserves the right to decline publication of a paper even after acceptance if there are serious problems with the scientific content or violations of its publishing policies. Nature Immunology's tight-knit research community means publication ethics issues circulate quickly among peers.
Sources
Free guide
AI cannot be an author. None of the 49 policies we checked allows it.
Not a co-author, not an acknowledged contributor with a byline, not "with assistance from". What they do require is a disclosure, and the wording matters. The guide has the statement filled in, with what each publisher asks for beside it.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Private API processing. Your manuscript is not used to train models.
Put the guidance to work
Choose the practical next step for your research.
Start with the question in front of you, or use the guided learning path when you want a clearer view of the full publishing process.
Where to go next
Start here
Same journal, next question
- Nature Immunology Submission Guide
- How to Avoid Desk Rejection at Nature Immunology
- Is Nature Immunology a Good Journal? Fit Verdict
- Is Your Paper Ready for Nature Immunology? The Fundamental Discovery Test
- Nature Immunology 'Under Review': What Each Status Means
- Nature Immunology Acceptance Rate: What Authors Can Use